Back to top
more

Karyopharm Therapeutics (KPTI)

(Delayed Data from NSDQ)

$1.28 USD

1.28
1,305,238

-0.10 (-7.25%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $1.27 -0.01 (-0.78%) 4:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KPTI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Karyopharm Therapeutics Inc. [KPTI]

Reports for Purchase

Showing records 1 - 20 ( 386 total )

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 1

03/01/2024

Company Report

Pages: 6

4Q23 Results; Data From Three Phase 3 Pivotal Studies Expected in 2025

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 2

01/09/2024

Company Report

Pages: 6

FY23 Preliminary Revenues Disappoint, But Focus Should be on New Indications in the Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 3

12/29/2023

Company Report

Pages: 4

Dropping Coverage

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 4

12/11/2023

Industry Report

Pages: 33

ASH 2023 Weekend Roundup for Covered Companies

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 35.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 5

11/06/2023

Daily Note

Pages: 3

Positive Updated Overall Survival Data For Xpovio in TP53 Wild-Type Endometrial Cancer Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 6

11/03/2023

Industry Report

Pages: 10

ASH 2023 Abstract Round Up for Covered Companies

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 7

11/03/2023

Company Report

Pages: 6

3Q23 Results; Xpovio Sales Slightly Above Our Expectations; Investor Focus Should Be on Ongoing Phase 3 Trials

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 8

11/02/2023

Company Report

Pages: 6

XPOVIO Contending with Challengers

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 9

10/30/2023

Daily Note

Pages: 4

Selinexor''s Collaboration with Mezigdomide

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 10

10/30/2023

Daily Note

Pages: 3

Clinical Trial Agreement With BMY For Mezigdomide in Combination With Xpovio and Dexamethasone in r/r MM Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 11

10/16/2023

Daily Note

Pages: 19

EORTC-NCI-AACR 2023: Roundup for Covered Companies

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 12

08/03/2023

Company Report

Pages: 8

2Q23 Results; Key Data Readouts Expected in 2024 and 2025

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 13

08/02/2023

Company Report

Pages: 5

As XPOVIO Demand Grows, Revenue Remains Flat

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 14

07/26/2023

Company Report

Pages: 8

Positive Updated Data From SIENDO Study Subgroup Analysis of Xpovio in TP53 WT Endometrial Cancer

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 15

07/26/2023

Daily Note

Pages: 10

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 16

07/26/2023

Company Report

Pages: 7

A While to Wait for SIENDO to Help Selinexor''s Sluggish Sales

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 17

07/18/2023

Daily Note

Pages: 3

Xpovio Receives Fast Track Designation From the FDA for the Treatment of Myelofibrosis

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 18

06/28/2023

Daily Note

Pages: 3

Initiation of Phase 3 Study of Xpovio and Jakafi in JAKi-Naive Patients With MF

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 19

06/02/2023

Industry Report

Pages: 127

Weekly Retail Sales Tracker for Solid Tumors - Week Ended May 26.

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 20

06/02/2023

Industry Report

Pages: 47

Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended May 26.

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party